Autonomic Modulation With Baroreflex Activation Therapy in Heart Failure

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Baroreflex activation therapy (BAT) produces a central inhibition of cardiac sympathetic outflow and, concomitantly, an increased cardiac vagal activity via a physiological reflex pathway. In a pilot study in 11 patients with NYHA class III heart failure (HF), BAT produced a persistent significant reduction of muscle sympathetic nerve activity over a 21-month follow-up and a dramatic decrease in the number and length of hospitalizations. In a multinational, prospective, randomized, parallel-controlled, clinical trial in 146 NYHA functional class III HF, BAT produced a significant N-terminal pro-brain natriuretic peptide reduction (p = 0.02). This was associated with a trend toward few in hospital days for HF. BAT might become a powerful tool to manipulate autonomic alterations of HF at their origin and thus profoundly affect advanced HF patient prognosis.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalCurrent Alzheimer Research
DOIs
Publication statusAccepted/In press - Nov 16 2016

Fingerprint

Baroreflex
Heart Failure
Therapeutics
Brain Natriuretic Peptide
Reflex
Hospitalization
Randomized Controlled Trials
Muscles

Keywords

  • Autonomic nervous system
  • Baroreflex activation
  • Heart failure
  • Non-pharmacologic therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Emergency Medicine

Cite this

@article{c2a67634be094efbb91b35db7c59bb68,
title = "Autonomic Modulation With Baroreflex Activation Therapy in Heart Failure",
abstract = "Baroreflex activation therapy (BAT) produces a central inhibition of cardiac sympathetic outflow and, concomitantly, an increased cardiac vagal activity via a physiological reflex pathway. In a pilot study in 11 patients with NYHA class III heart failure (HF), BAT produced a persistent significant reduction of muscle sympathetic nerve activity over a 21-month follow-up and a dramatic decrease in the number and length of hospitalizations. In a multinational, prospective, randomized, parallel-controlled, clinical trial in 146 NYHA functional class III HF, BAT produced a significant N-terminal pro-brain natriuretic peptide reduction (p = 0.02). This was associated with a trend toward few in hospital days for HF. BAT might become a powerful tool to manipulate autonomic alterations of HF at their origin and thus profoundly affect advanced HF patient prognosis.",
keywords = "Autonomic nervous system, Baroreflex activation, Heart failure, Non-pharmacologic therapy",
author = "Edoardo Gronda and Emilio Vanoli",
year = "2016",
month = "11",
day = "16",
doi = "10.1007/s11897-016-0307-7",
language = "English",
pages = "1--8",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Autonomic Modulation With Baroreflex Activation Therapy in Heart Failure

AU - Gronda, Edoardo

AU - Vanoli, Emilio

PY - 2016/11/16

Y1 - 2016/11/16

N2 - Baroreflex activation therapy (BAT) produces a central inhibition of cardiac sympathetic outflow and, concomitantly, an increased cardiac vagal activity via a physiological reflex pathway. In a pilot study in 11 patients with NYHA class III heart failure (HF), BAT produced a persistent significant reduction of muscle sympathetic nerve activity over a 21-month follow-up and a dramatic decrease in the number and length of hospitalizations. In a multinational, prospective, randomized, parallel-controlled, clinical trial in 146 NYHA functional class III HF, BAT produced a significant N-terminal pro-brain natriuretic peptide reduction (p = 0.02). This was associated with a trend toward few in hospital days for HF. BAT might become a powerful tool to manipulate autonomic alterations of HF at their origin and thus profoundly affect advanced HF patient prognosis.

AB - Baroreflex activation therapy (BAT) produces a central inhibition of cardiac sympathetic outflow and, concomitantly, an increased cardiac vagal activity via a physiological reflex pathway. In a pilot study in 11 patients with NYHA class III heart failure (HF), BAT produced a persistent significant reduction of muscle sympathetic nerve activity over a 21-month follow-up and a dramatic decrease in the number and length of hospitalizations. In a multinational, prospective, randomized, parallel-controlled, clinical trial in 146 NYHA functional class III HF, BAT produced a significant N-terminal pro-brain natriuretic peptide reduction (p = 0.02). This was associated with a trend toward few in hospital days for HF. BAT might become a powerful tool to manipulate autonomic alterations of HF at their origin and thus profoundly affect advanced HF patient prognosis.

KW - Autonomic nervous system

KW - Baroreflex activation

KW - Heart failure

KW - Non-pharmacologic therapy

UR - http://www.scopus.com/inward/record.url?scp=84995422324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995422324&partnerID=8YFLogxK

U2 - 10.1007/s11897-016-0307-7

DO - 10.1007/s11897-016-0307-7

M3 - Article

SP - 1

EP - 8

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

ER -